11 Comments
 

That's not really surprising, Piper's FIG division has always been strong since the Piper Sandler merger. Overall Piper is a solid MM, as it's always been, with certain groups (FIG from Sandler, Chemicals from Valence, and MedTech) punching above the firm's overall weight and MM reputation. C&R is also a strong group within the MM space, and while Tech's traditionally been weak the DBO acquisition should help boost things. Rest of the groups are middle-of-the-road MM groups.

 

Sandler has historically always punched way above its weight in FIG. Pre-Piper merger they would consistently lead the FIG league tables alongside GS and MS (I believe MS was the other really large player, but I know for certain Sandler was always a top 3 - 5 player). If you have any interest in FIG Sandler is one of the best shops in the US. 

 
Most Helpful

Piper Sandler's inorganic growth strategy has been phenomenal and they have definitely come a long way since the early 2010's. With this growth trajectory, I can easily see them becoming the #1 MM bank very soon, if they aren't already, given the Blair situation. The only thing I would criticize is the imbalance of strength across Piper's groups. Their strong groups are much stronger than the same sector groups in other MM's, while their weaker groups are weaker than the same sector groups in other MM's (if that makes sense). However, it does seem that they have been compensating by simply just acquiring the best boutiques and buying their way to the top, and it's really been working. If recruiting for Piper, I would recommend these groups:

  • Chemicals (Valence Group) - one of the best, if not the best chemicals group on the street. Several multi-billion dollar deals a year (biggest deals at Piper), with solid PE exits and true senior specialists (Ex Bear Stearns Chemicals team).
  • FIG (Sandler O' Neill) - top notch FIG team on the street, along with Goldman, Lazard, KBW, Barclays, MS. Analysts have regularly exited to HF/PE, with some cracking MF.
  • Tech (DBO Partners) - DBO Partners was an amazing boutique before the acquisition. Seniors are ex-MS tech, and analysts are all from Stanford/Haas/Penn/Dartmouth and the exits are phenomenal (UMM/MF). The thing about this one is that I'm not sure how they are currently integrated within Piper, as their in-house tech team is quite weak. I believe DBO still operates independently in Burlingame, California, while the original tech team sits in SF. Anyways, would definitely aim for the Burlingame office if interested in tech. 
 

I understand your rankings with FIG and chemicals, but why didn’t you put healthcare in the mix? I’ve always thought of Piper as a dominant player in the healthcare space given that Minneapolis is a healthcare hub and Piper has a lot of those firms in their pocket. Also, I really like your thoughts about Piper tech, I think they have a lot of big things coming their way with the DBO acquisition.

 

Yep I agree they are decently strong in HC, but I think Blair, Jeff, HL, maybe HW, are all better in that segment no? The groups i listed above (chemicals, FIG, Tech (DBO)) all punch above their weight class and are by far better than any chem/fig/tech group in the middle market. Those groups regularly compete with EB's/BB's and beat them out.

 

Quis quo perferendis quia. Natus aut explicabo dolores et minima. Et molestiae molestiae et recusandae dicta sit. Sunt nesciunt perferendis consequatur occaecati in. Est id laboriosam quod voluptatem.

Qui voluptas id aut omnis consectetur perspiciatis. Saepe sint sed est dignissimos nisi. Ut a accusantium est praesentium ut neque.

Laboriosam aut unde tempora omnis deleniti rerum assumenda. Rerum dignissimos earum iure voluptas. Incidunt nam est vitae ea perferendis reiciendis alias. Eligendi aut est reprehenderit et. Eum molestias qui dolorem dignissimos pariatur doloribus sint illo. Consequatur est numquam commodi beatae.

Rerum aut qui debitis est numquam. Aperiam animi est unde animi. Sed quae veniam quis dolor fuga. Quia quia et commodi et tenetur quia modi. Aut omnis eveniet est perspiciatis inventore. Fugiat quisquam voluptatibus molestias. Magni aut quaerat quia aperiam.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (67) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
dosk17's picture
dosk17
98.9
6
CompBanker's picture
CompBanker
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”